Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy

被引:13
|
作者
Plotnikov, Alexander
Niego, Be'eri
Ophir, Rachel
Korenstein, Rafi
Keisari, Yona [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel
来源
PROSTATE | 2006年 / 66卷 / 15期
关键词
electrostimulation; prostate cancer; immunostimulation; chemotherapy; low electric field;
D O I
10.1002/pros.20435
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. We developed a new anti-cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinorna of mice (TRAMP). METHODS. Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth. RESULTS. The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT-EC reduced tumor size, prolonged survival, and cured 36-93% of the animals, dependent on treated tumor size. LEFCT-EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti-tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment. CONCLUSION. Our results suggest that LEFCT-EC is an effective method for the destruction of metastatic prostate tumors.
引用
收藏
页码:1620 / 1630
页数:11
相关论文
共 50 条
  • [1] Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer
    Zhao, Janice
    Guercio, Brendan J.
    Sahasrabudhe, Deepak
    CANCERS, 2023, 15 (15)
  • [2] AN EPIDEMIOLOGICAL EVALUATION OF CHEMOTHERAPY USED IN THE TREATMENT OF METASTATIC PROSTATE CANCER
    Chevalier, P.
    Moeremans, K.
    VALUE IN HEALTH, 2011, 14 (07) : A468 - A468
  • [3] Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem
    Alekseev, B. Ya.
    ONKOUROLOGIYA, 2015, 11 (03): : 108 - 116
  • [4] Abiraterone for the treatment of metastatic prostate cancer without previous chemotherapy
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (03) : 220 - 220
  • [5] The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer
    Luis Perez-Gracia, Jose
    Diez Caballero, Fernando
    Gurpide, Alfonso
    de Fata Chillon, Fernando Ramon
    Villacampa, Felipe
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (03): : 276 - 280
  • [6] Upfront Chemotherapy for Metastatic Prostate Cancer
    Lam, Elaine T.
    Flaig, Thomas W.
    ONCOLOGY-NEW YORK, 2015, 29 (12): : 956 - 962
  • [7] The role of chemotherapy in metastatic prostate cancer
    Riaz, Irbaz B.
    Sweeney, Christopher J.
    CURRENT OPINION IN UROLOGY, 2022, 32 (03) : 292 - 301
  • [8] EXPERIENCE WITH CHEMOTHERAPY OF METASTATIC CANCER OF THE PROSTATE
    GRAFF, J
    PASTOR, J
    BERTELS, C
    DEMETRIOU, D
    SCHULZE, H
    AKTUELLE UROLOGIE, 1990, 21 (01) : 1 - 6
  • [9] Chemotherapy research for metastatic prostate cancer
    Kapoor, Anil
    Hotte, Sebastien J.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (7-8): : S140 - S143
  • [10] Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
    Sternberg, C. N.
    ANNALS OF ONCOLOGY, 2008, 19 : 91 - 95